ONCOVIR
Oncovir is a pharmaceutical company dedicated to the development of nucleic-acid-based clinical therapies for cancer, infectious, immune, and degenerative disorders. It promotes Hiltonol (poly-ICLC) as an experimental viral mimic and broad activator of innate immunity. While initially developed as an interferon inducer, Hiltonol has much broader biological effects in humans, including specific antiviral, immune activating, vaccine adjuvant, and antitumor actions.
ONCOVIR
Industry:
Biotechnology Clinical Trials Health Care Medical
Address:
Washington, District Of Columbia, United States
Country:
United States
Status:
Active
Similar Organizations
Clinical Research of Central Florida
Clinical Research of Central Florida is dedicated to the advancement of clinical trials in all areas of research.
Entos Pharmaceuticals
Entos Pharmaceuticals is a healthcare biotechnology company that develops nucleic acid therapies.
Novamind
Novamind is a mental health company enabling safe access to psychedelic medicine through a network of clinics and clinical research sites.
Taiho Oncology
Taiho Oncology is a pharmaceutical company that specializes in developing innovative cancer treatments.
Current Employees Featured
More informations about "Oncovir"
Oncovir - Crunchbase Company Profile & Funding
Oncovir is a pharmaceutical company dedicated to the development of nucleic-acid-based clinical therapies for cancer, infectious, immune, and degenerative disorders. It promotes Hiltonol …See details»
Oncovir Company Profile 2024: Valuation, Funding
Oncovir General Information Description. Operator of a pharmaceutical corporation dedicated to the development of nucleic-acid-based clinical therapies for cancer, infectious, immune and degenerative disorders. The company's …See details»
Cancer Research Institute Announces Second Investment from Its …
Jan 21, 2011 Cancer Research Institute, Inc. (CRI), a U.S. nonprofit organization founded in 1953 to advance the science of tumor immunology and foster the discovery and development …See details»
Oncovir, Inc. - LinkedIn
Oncovir, Inc is a pharmaceutical corporation dedicated to the development of nucleic-acid-based clinical therapies for cancer, infectious, immune, and degenerative disorders. We promote …See details»
Oncovir Inc - Company Profile and News - Bloomberg Markets
Company profile page for Oncovir Inc including stock price, company news, executives, board members, and contact informationSee details»
Organization | Oncovir, Inc.
Oncovir, Inc. Report issue. For profit Phase 1 Phase 2. Founded: Washington DC United States (2011 ... Organization Overview. First Clinical Trial. 2011 NCT00374049. First Marketed Drug. …See details»
Oncovir, Inc. is Pushing the Boundaries of Medical …
Mar 8, 2024 The Oncovir, Inc. team is focused on collaboration and innovation. Despite geographical distances, the team stays connected daily to ensure the continued alignment and forward progress of their ...See details»
Exhibit - SEC.gov
1.4 “Change of Control” means, with respect to ONCOVIR, (a) a merger or consolidation of ONCOVIR with a third party which results in the voting securities of ONCOVIR outstanding …See details»
Oncovir, Inc Company Profile | Winchester, VA - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Oncovir, Inc of Winchester, VA. Get the latest business insights from Dun & Bradstreet.See details»
Dalton and Oncovir Enter Into a Manufacturing Services Agreement
Feb 3, 2011 The Cancer Research Institute (CRI), established in 1953, is the world's only nonprofit organization dedicated exclusively to transforming cancer patient care by advancing …See details»
Oncovir - Company Profile - Tracxn
Dec 5, 2024 Oncovir is currently collaborating in two dozen separate ongoing or completed phase I-II clinical trials using Hiltonol® alone or combined with a variety of therapeutic or …See details»
Oncovir, Inc. on LinkedIn: Oncovir, Inc. is Pushing the Boundaries …
At Oncovir, our commitment to developing cutting-edge treatments and providing unparalleled support for patients' quality of life remains steadfast. While conquering cancer is undoubtedly ...See details»
Oncovir Inc. - BioCentury Company Profiles - BCIQ
Sep 14, 2017 Oncovir Inc. - BioCentury Company Profiles for the biopharma industrySee details»
Andres M - Chairman & CEO - Oncovir, Inc | LinkedIn
Oncovir, Inc. Winchester, VA. Connect Matthew Vandermast Washington DC-Baltimore Area. Connect Brian W. Pusch New York, NY. Connect Howard Bahnsen Chairman & CEO at …See details»
Designing therapeutic cancer vaccines by mimicking viral …
Apr 6, 2016 The rights of the patent applications have been transferred to the Moffitt Cancer Center (Tampa, FL). Andres Salazar is President and CEO of Oncovir, Inc., who is developing …See details»
Vaccine adjuvant uses of poly-IC and derivatives - Taylor & Francis …
Oct 13, 2014 AM Salazar is CEO of Oncovir, Inc. and is both employed by and owns stock in Oncovir, Inc., which is developing poly-ICLC. S Bavari is a US federal government employee. …See details»
Poly-ICLC, a TLR3 Agonist, Induces Transient Innate Immune …
A .gov website belongs to an official government organization in the United States. Secure .gov websites use HTTPS A lock Locked padlock icon ... AS is the CEO and Scientific Director of …See details»
Oncovir, Inc. | Institution outputs | Nature Index
Oncovir, Inc. Oncovir, Inc. United States of America (USA) Page navigation. Research Research. Date range: 1 November 2022 - 31 October 2023. No articles found. Oncovir, Inc ...See details»
Therapeutic in situ autovaccination against solid cancers with ...
5 Oncovir, Inc., Washington, District of Columbia; PMID: 24801836 DOI: 10.1158/2326-6066.CIR-14-0024 Abstract Pathogen-associated molecular patterns (PAMP) are stand-alone innate and …See details»
Poly ICLC - Oncovir - AdisInsight - Springer
If your organization has a subscription, there are several access options, even while working remotely: Working within your organization’s network Login with username/password or try to …See details»